Sort
48,018 grants matching “immunotherapy”
A Novel Immunological-Directed Probiotic for the Treatment of Sjögrenâs Syndrome
$429,158Gary Fanger · Rise Therapeutics, Llc · UG3 · FY2025 · DE
Immunotherapy for Drug Abuse
$429,148S. Michael Owens · Univ Of Arkansas For Med Scis · R01 · FY2008 · DA
Investigational Cancer Therapeutics Training Program
$429,125Mark G Kris · Sloan-Kettering Inst Can Research · T32 · FY2014 · CA
Blockade of colony stimulating factor 1 receptor to reduce inflammatory nerve injury
$429,000Kazim A Sheikh · University Of Texas Hlth Sci Ctr Houston · R21 · FY2021 · NS
Targeting miRNA-loaded exosomes to HNSCC with Dsg2-directed scFv fusion proteins
$429,000My Georgia Mahoney · Thomas Jefferson University · R21 · FY2024 · DE
Transdiagnostic and Disorder-Specific Effects of Immune and Metabolic Factors on Motivational Deficits Across Mood and Psychotic Disorders
$429,000Michael Tilghman Treadway · Emory University · R21 · FY2020 · MH
Glutathione depletion in the CNS and its effects on Mtb infection
$429,000Vishwanath Venketaraman · Western University Of Health Sciences · R15 · FY2024 · HL
Chemo-immunotherapy strategy for pediatric high grade glioma
$429,000Maria G Castro · University Of Michigan At Ann Arbor · R21 · FY2021 · NS
Tau pathology in neurons, glia, and cell type-specific exosomes from cryopreserved AD cortex
$429,000Tina Bilousova · University Of California Los Angeles · R21 · FY2020 · AG
Immunomodulatory effects of desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in mucosal pemphigus vulgaris
$429,000Aimee S Payne · University Of Pennsylvania · R01 · FY2023 · AR
Clinical Trials in Mesothelioma
$428,952Daniel Sterman · University Of Pennsylvania · P01 · FY2010 · CA
A Phase I Study of Lentivirus Safety During T-Cell Immu
$428,913John A Zaia · Beckman Research Institute/City Of Hope · P01 · FY2006 · AI
Physical Resistance to Immune Cell Attack by the Cellular Glycocalyx
$428,910Matthew J Paszek · Cornell University · R01 · FY2024 · CA
Preventing follicular lymphoma progression and transformation through precision therapy
$428,795Wendy Beguelin · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
The role of TIM-3 in regulating T cell function during tuberculosis
$428,728Samuel M Behar · Brigham And Women'S Hospital · P01 · FY2016 · AI
Enhanced imaging and treatment of aggressive subtypes of prostate cancer
$428,718Martin G Pomper · Ut Southwestern Medical Center · R01 · FY2024 · CA
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
$428,711Paul Nghiem · University Of Washington · P01 · FY2021 · CA
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
$428,694Joseph Kissil · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
$428,692Joseph Kissil · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Therapeutic Manufacturing Shared Resource
$428,687Zita Mears · Fred Hutchinson Cancer Center · P30 · FY2025 · CA
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma
$428,676Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
Spatial and temporal tumor-immune co-evolution and interactions that model lung adenocarcinoma development
$428,656Humam Kadara · University Of Tx Md Anderson Can Ctr · U01 · FY2023 · CA
ROLE OF IDOLEAMINE 2.3 DIOXYGENASE (IDO) IN BREAST CANCER METASTASIS FORMATION AND IMMUNOTHERAPY
$428,653University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2008 · Department of Defense
Elucidating the role of T-regs in engraftment, GVHD, and DLI immunotherapy
$428,585Christene A Huang · Massachusetts General Hospital · R01 · FY2010 · AI
Targeting HSP70 for MelanomaTherapy
$428,529Maureen E Murphy · Wistar Institute · P01 · FY2020 · CA